{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T10:50:43Z","timestamp":1791370243543,"version":"4.3.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["62220106006"],"award-info":[{"award-number":["62220106006"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203755"],"award-info":[{"award-number":["82203755"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-025-03985-4","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T13:18:53Z","timestamp":1741699133000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Efficacy and safety of cadonilimab (PD-1\/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial"],"prefix":"10.1186","volume":"23","author":[{"given":"Yaofei","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixin","family":"Bei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nian","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangru","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuiqing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhui","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanrun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuguang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixiong","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqun","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"key":"3985_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","volume":"10192","author":"Y-P Chen","year":"2019","unstructured":"Chen Y-P, Chan ATC, Le Q-T, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;10192:64\u201380.","journal-title":"Lancet"},{"key":"3985_CR2","first-page":"22","volume":"1","author":"R-M Feng","year":"2019","unstructured":"Feng R-M, Zong Y-N, Cao S-M, Xu R-H. Current cancer situation in China: good or bad news from the 2018 global cancer statistics? Cancer Commun (Lond). 2019;1:22.","journal-title":"Cancer Commun (Lond)"},{"key":"3985_CR3","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3390\/cancers10070210","volume":"7","author":"HL Ngan","year":"2018","unstructured":"Ngan HL, Wang L, Lo KW, Lui VWY. Genomic landscapes of EBV-associated nasopharyngeal carcinoma vs. HPV-associated head and neck cancer. Cancers (Basel). 2018;7:210.","journal-title":"Cancers (Basel)"},{"key":"3985_CR4","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1016\/S0140-6736(16)31388-5","volume":"10054","author":"L Zhang","year":"2016","unstructured":"Zhang L, Huang Y, Hong S, Yang Y, Yu G, Jia J, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet. 2016;10054:1883\u201392.","journal-title":"Lancet"},{"key":"3985_CR5","doi-asserted-by":"publisher","first-page":"101890","DOI":"10.1016\/j.ctrv.2019.101890","volume":"79","author":"AWM Lee","year":"2019","unstructured":"Lee AWM, Ng WT, Chan JYW, Corry J, M\u00e4kitie A, Mendenhall WM, et al. Management of locally recurrent nasopharyngeal carcinoma. Cancer Treat Rev. 2019;79:101890.","journal-title":"Cancer Treat Rev."},{"key":"3985_CR6","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s41591-021-01444-0","volume":"9","author":"H-Q Mai","year":"2021","unstructured":"Mai H-Q, Chen Q-Y, Chen D, Hu C, Yang K, Wen J, et al. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. Nat Med. 2021;9:1536\u201343.","journal-title":"Nat Med"},{"key":"3985_CR7","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/S1470-2045(21)00302-8","volume":"8","author":"Y Yang","year":"2021","unstructured":"Yang Y, Qu S, Li J, Hu C, Xu M, Li W, et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2021;8:1162\u201374.","journal-title":"Lancet Oncol"},{"issue":"6","key":"3985_CR8","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ccell.2023.04.014","volume":"41","author":"Y Yang","year":"2023","unstructured":"Yang Y, Pan J, Wang H, Zhao Y, Qu S, Chen N, et al. Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: a multicenter phase 3 trial (RATIONALE-309). Cancer Cell. 2023;41(6):1061-1072.e4.","journal-title":"Cancer Cell."},{"key":"3985_CR9","doi-asserted-by":"publisher","first-page":"104113","DOI":"10.1016\/j.critrevonc.2023.104113","volume":"190","author":"Y Jiang","year":"2023","unstructured":"Jiang Y, Fang T, Lu N, Bei W, Dong S, Xia W, et al. Anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR treatment beyond progression in recurrent\/metastatic nasopharyngeal carcinoma patients. Crit Rev Oncol Hematol. 2023;190:104113.","journal-title":"Crit Rev Oncol Hematol."},{"key":"3985_CR10","doi-asserted-by":"publisher","first-page":"102043","DOI":"10.1016\/j.eclinm.2023.102043","volume":"61","author":"X Ding","year":"2023","unstructured":"Ding X, Hua YJ, Zou X, Chen XZ, Zhang XM, Xu B, et al. Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study. EClinicalMedicine. 2023;61:102043.","journal-title":"EClinicalMedicine"},{"key":"3985_CR11","doi-asserted-by":"publisher","first-page":"4893","DOI":"10.1038\/s41467-023-40402-x","volume":"1","author":"L Yuan","year":"2023","unstructured":"Yuan L, Jia G-D, Lv X-F, Xie S-Y, Guo S-S, Lin D-F, et al. Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent\/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial. Nat Commun. 2023;1:4893.","journal-title":"Nat Commun"},{"key":"3985_CR12","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s40265-022-01761-9","volume":"12","author":"SJ Keam","year":"2022","unstructured":"Keam SJ. Cadonilimab: first approval. Drugs. 2022;12:1333\u20139.","journal-title":"Drugs"},{"key":"3985_CR13","doi-asserted-by":"publisher","first-page":"2180794","DOI":"10.1080\/19420862.2023.2180794","volume":"1","author":"X Pang","year":"2023","unstructured":"Pang X, Huang Z, Zhong T, Zhang P, Wang ZM, Xia M, et al. Cadonilimab, a tetravalent PD-1\/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity. MAbs. 2023;1:2180794.","journal-title":"MAbs"},{"key":"3985_CR14","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/S1470-2045(23)00411-4","volume":"10","author":"X Gao","year":"2023","unstructured":"Gao X, Xu N, Li Z, Shen L, Ji K, Zheng Z, et al. Safety and antitumour activity of cadonilimab, an anti-PD-1\/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b\/2 trial. Lancet Oncol. 2023;10:1134\u201346.","journal-title":"Lancet Oncol"},{"key":"3985_CR15","doi-asserted-by":"publisher","first-page":"101242","DOI":"10.1016\/j.xcrm.2023.101242","volume":"11","author":"S Frentzas","year":"2023","unstructured":"Frentzas S, Gan HK, Cosman R, Coward J, Tran B, Millward M, et al. A phase 1a\/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors. Cell Rep Med. 2023;11:101242.","journal-title":"Cell Rep Med"},{"key":"3985_CR16","doi-asserted-by":"publisher","first-page":"1238667","DOI":"10.3389\/fimmu.2023.1238667","volume":"14","author":"Q Qiao","year":"2023","unstructured":"Qiao Q, Han C, Ye S, Li J, Shao G, Bai Y, et al. The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib\/II single-arm clinical trial. Front Immunol. 2023;14:1238667.","journal-title":"Front Immunol."},{"key":"3985_CR17","doi-asserted-by":"publisher","first-page":"106723","DOI":"10.1016\/j.oraloncology.2024.106723","volume":"151","author":"QY Chen","year":"2024","unstructured":"Chen QY, Guo SS, Luo Y, Qu S, Wu DH, Chen XZ, et al. Efficacy and safety of cadonilimab in previously treated recurrent or metastatic nasopharyngeal carcinoma(COMPASSION-06): a phase II multicenter study. Oral Oncol. 2024;151:106723.","journal-title":"Oral Oncol."},{"key":"3985_CR18","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1001\/jamaoncol.2022.0122","volume":"5","author":"W-Z Li","year":"2022","unstructured":"Li W-Z, Lv X, Hu D, Lv S-H, Liu G-Y, Liang H, et al. Effect of induction chemotherapy with paclitaxel, cisplatin, and capecitabine vs cisplatin and fluorouracil on failure-free survival for patients with stage IVA to IVB nasopharyngeal carcinoma: a multicenter phase 3 randomized clinical trial. JAMA Oncol. 2022;5:706\u201314.","journal-title":"JAMA Oncol"},{"key":"3985_CR19","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1001\/jamaoncol.2021.7366","volume":"4","author":"G-Y Liu","year":"2022","unstructured":"Liu G-Y, Li W-Z, Wang D-S, Liang H, Lv X, Ye Y-F, et al. Effect of capecitabine maintenance therapy plus best supportive care vs best supportive care alone on progression-free survival among patients with newly diagnosed metastatic nasopharyngeal carcinoma who had received induction chemotherapy: a phase 3 randomized clinical trial. JAMA Oncol. 2022;4:553\u201361.","journal-title":"JAMA Oncol"},{"key":"3985_CR20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1200\/JCO.22.00221","volume":"1","author":"A Arance","year":"2023","unstructured":"Arance A, de la Cruz-Merino L, Petrella TM, Jamal R, Ny L, Carneiro A, et al. Phase II LEAP-004 Study of lenvatinib plus pembrolizumab for melanoma with confirmed progression on a programmed cell death protein-1 or programmed death ligand 1 inhibitor given as monotherapy or in combination. J Clin Oncol. 2023;1:75\u201385.","journal-title":"J Clin Oncol"},{"key":"3985_CR21","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","volume":"8","author":"A Ribas","year":"2015","unstructured":"Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;8:908\u201318.","journal-title":"Lancet Oncol"},{"key":"3985_CR22","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1200\/JCO.21.00079","volume":"24","author":"DJ Olson","year":"2021","unstructured":"Olson DJ, Eroglu Z, Brockstein B, Poklepovic AS, Bajaj M, Babu S, et al. Pembrolizumab plus ipilimumab following anti-PD-1\/L1 failure in melanoma. J Clin Oncol. 2021;24:2647\u201355.","journal-title":"J Clin Oncol"},{"key":"3985_CR23","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.21873\/anticanres.13543","volume":"7","author":"K Fujita","year":"2019","unstructured":"Fujita K, Uchida N, Yamamoto Y, Kanai O, Okamura M, Nakatani K, et al. Retreatment with anti-PD-L1 antibody in advanced non-small cell lung cancer previously treated with anti-PD-1 antibodies. Anticancer Res. 2019;7:3917\u201321.","journal-title":"Anticancer Res"},{"key":"3985_CR24","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.annonc.2021.10.009","volume":"2","author":"R Kim","year":"2022","unstructured":"Kim R, Kwon M, An M, Kim ST, Smith SA, Loemb\u00e9 AB, et al. Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced\/metastatic melanoma who have failed prior anti-PD-1 therapy. Ann Oncol. 2022;2:193\u2013203.","journal-title":"Ann Oncol"},{"key":"3985_CR25","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"4","author":"JS Weber","year":"2015","unstructured":"Weber JS, D\u2019Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;4:375\u201384.","journal-title":"Lancet Oncol"},{"key":"3985_CR26","doi-asserted-by":"publisher","first-page":"107355","DOI":"10.1016\/j.lungcan.2023.107355","volume":"184","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Ma Y, Fan Y, Zhou J, Yang N, Yu Q, et al. A multicenter, open-label phase Ib\/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104\u2013202 study). Lung Cancer. 2023;184:107355.","journal-title":"Lung Cancer."},{"key":"3985_CR27","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1038\/s41467-023-38407-7","volume":"1","author":"DW-T Lim","year":"2023","unstructured":"Lim DW-T, Kao H-F, Suteja L, Li CH, Quah HS, Tan DS-W, et al. Clinical efficacy and biomarker analysis of dual PD-1\/CTLA-4 blockade in recurrent\/metastatic EBV-associated nasopharyngeal carcinoma. Nat Commun. 2023;1:2781.","journal-title":"Nat Commun."},{"key":"3985_CR28","doi-asserted-by":"publisher","first-page":"e204564","DOI":"10.1001\/jamaoncol.2020.4564","volume":"11","author":"T Yau","year":"2020","unstructured":"Yau T, Kang Y-K, Kim T-Y, El-Khoueiry AB, Santoro A, Sangro B, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial. JAMA Oncol. 2020;11:e204564.","journal-title":"JAMA Oncol"},{"key":"3985_CR29","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"10272","author":"P Baas","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;10272:375\u201386.","journal-title":"Lancet"},{"key":"3985_CR30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","volume":"1","author":"MD Hellmann","year":"2017","unstructured":"Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN, Borghaei H, Brahmer JR, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2017;1:31\u201341.","journal-title":"Lancet Oncol"},{"key":"3985_CR31","doi-asserted-by":"publisher","first-page":"e220587","DOI":"10.1001\/jamanetworkopen.2022.0587","volume":"3","author":"J-Y Xu","year":"2022","unstructured":"Xu J-Y, Wei X-L, Ren C, Zhang Y, Hu Y-F, Li J-Y, et al. Association of plasma Epstein-Barr Virus DNA with outcomes for patients with recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 immunotherapy. JAMA Netw Open. 2022;3:e220587.","journal-title":"JAMA Netw Open"},{"key":"3985_CR32","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1200\/JCO.20.02712","volume":"7","author":"F-H Wang","year":"2021","unstructured":"Wang F-H, Wei X-L, Feng J, Li Q, Xu N, Hu X-C, et al. Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02). J Clin Oncol. 2021;7:704\u201312.","journal-title":"J Clin Oncol"},{"key":"3985_CR33","first-page":"12","volume":"12","author":"Y Yang","year":"2021","unstructured":"Yang Y, Zhou T, Chen X, Li J, Pan J, He X, et al. Efficacy, safety, and biomarker analysis of camrelizumab in previously treated recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN study). J Immunother Cancer. 2021;12:12.","journal-title":"J Immunother Cancer."},{"key":"3985_CR34","doi-asserted-by":"publisher","first-page":"600","DOI":"10.3389\/fonc.2020.00600","volume":"10","author":"PM Hau","year":"2020","unstructured":"Hau PM, Lung HL, Wu M, Tsang CM, Wong KL, Mak NK, et al. Targeting Epstein-Barr virus in nasopharyngeal carcinoma. Front Oncol. 2020;10:600.","journal-title":"Front Oncol"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-03985-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-03985-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-03985-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T13:18:55Z","timestamp":1741699135000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-025-03985-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3985"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-03985-4","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]},"assertion":[{"value":"15 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Study procedures were approved by the institutional review boards of the Sun Yat-Sen University Cancer Center (B2022-722), and all patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients had provided informed consent for the participants in the study and publication of any associated data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"152"}}